INS and diabetes mellitus: Recent evidence, however, shows the ability of Bcl-2 and Bcl-xL to protect human β-cells without impairing insulin release, introducing a promising avenue for β-cell-specific therapies aimed at preventing β-cell loss during diabetes progression.